XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) Short Interest Down 97.2% in May

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) was the recipient of a significant decrease in short interest during the month of May. As of May 15th, there was short interest totaling 19,218 shares, a decrease of 97.2% from the April 30th total of 680,467 shares. Based on an average daily volume of 239,726 shares, the short-interest ratio is currently 0.1 days. Currently, 1.2% of the shares of the stock are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of XTL Biopharmaceuticals in a research note on Thursday, April 2nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has a consensus rating of “Sell”.

XTL Biopharmaceuticals Trading Up 2.1%

XTL Biopharmaceuticals stock traded up $0.05 during mid-day trading on Wednesday, reaching $2.43. The company had a trading volume of 10,464 shares, compared to its average volume of 1,297,269. XTL Biopharmaceuticals has a fifty-two week low of $2.12 and a fifty-two week high of $10.28. The company has a market cap of $5.35 million, a P/E ratio of -3.80 and a beta of 1.64. The business has a fifty day simple moving average of $2.59 and a 200 day simple moving average of $5.45.

About XTL Biopharmaceuticals

XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel.